Literature DB >> 3437384

Comparative distribution kinetics of cefazolin and tobramycin in children.

R Koshida1, E Nakashima, F Ichimura, O Nakano, R Watanabe, N Taniguchi, A Tsuji.   

Abstract

The time courses of drug concentration in serum after i.v. drip infusion of 2 mg/kg of tobramycin and 25 mg/kg of cefazolin in children were analyzed by model-independent moment analysis. The volume of distribution at the steady state per body weight (Vdss/BW) of tobramycin was in the range of 212 to 335 ml/kg and that of cefazolin was 119 to 156 ml/kg. A plot of the differences of Vdss/BW obtained in the same child for tobramycin and cefazolin against the value of Vdss/BW of tobramycin gave a linear regression line (r = 0.971). The magnitude of Vdss (1) of tobramycin could be well interpreted as corresponding to the extracellular water volume. In the case of cefazolin, the extracellular water space accounts for about 60% of the total distribution volume. The remaining 40% of the total Vdss of cefazolin was considered to be accounted for by the disposing organs.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3437384     DOI: 10.1248/bpb1978.10.436

Source DB:  PubMed          Journal:  J Pharmacobiodyn        ISSN: 0386-846X


  7 in total

1.  Pharmacokinetics and drug dosing in obese children.

Authors:  Jennifer G Kendrick; Roxane R Carr; Mary H H Ensom
Journal:  J Pediatr Pharmacol Ther       Date:  2010-04

2.  Determination of appropriate weight-based cutoffs for empiric cefazolin dosing using data from a phase 1 pharmacokinetics and safety study of cefazolin administered for surgical prophylaxis in pediatric patients aged 10 to 12 years.

Authors:  Michael L Schmitz; Jeffrey L Blumer; Wes Cetnarowski; Christopher M Rubino
Journal:  Antimicrob Agents Chemother       Date:  2015-05-04       Impact factor: 5.191

Review 3.  Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.

Authors:  J Singh; B Burr; D Stringham; A Arrieta
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

4.  An Overview of the Protein Binding of Cephalosporins in Human Body Fluids: A Systematic Review.

Authors:  C Jongmans; A E Muller; P Van Den Broek; B De Melo Cruz De Almeida; C Van Den Berg; J Van Oldenrijk; P K Bos; B C P Koch
Journal:  Front Pharmacol       Date:  2022-06-28       Impact factor: 5.988

5.  Cefazolin plasma protein binding and its covariates in neonates.

Authors:  A Smits; A Kulo; R Verbesselt; G Naulaers; J de Hoon; P Vermeersch; K Allegaert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-07-26       Impact factor: 3.267

6.  Prediction of the distribution volumes of cefazolin and tobramycin in obese children based on physiological pharmacokinetic concepts.

Authors:  R Koshida; E Nakashima; N Taniguchi; A Tsuji; L Z Benet; F Ichimura
Journal:  Pharm Res       Date:  1989-06       Impact factor: 4.200

7.  Cefazolin pharmacokinetics in premature infants.

Authors:  Stephen J Balevic; P Brian Smith; Daniela Testoni; Huali Wu; Kim L R Brouwer; Kanecia O Zimmerman; Nazario D Rivera-Chaparro; Daniel K Benjamin; Michael Cohen-Wolkowiez
Journal:  J Perinatol       Date:  2019-04-03       Impact factor: 3.225

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.